2024
DOI: 10.1017/dmp.2023.226
|View full text |Cite
|
Sign up to set email alerts
|

Radiation and Chemical Program Research for Multi-Utility and Repurposed Countermeasures: A US Department of Health and Human Services Agencies Perspective

Carmen I. Rios,
Efrain E. Garcia,
Thomas S. Hogdahl
et al.

Abstract: Although chemical and radiological agents cause toxicity through different mechanisms, the multiorgan injuries caused by these threats share similarities that convene on the level of basic biological responses. This publication will discuss these areas of convergence and explore “multi-utility” approaches that could be leveraged to address common injury mechanisms underlying actions of chemical and radiological agents in a threat-agnostic manner. In addition, we will provide an overview of the current state of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 68 publications
0
1
0
Order By: Relevance
“…Marzella’s article addresses the importance of aligning mechanisms of action and clinical conditions in animal models of radiation and chemical threat agents and their use in selecting a maximally effective dose in humans. Rios 10 examines the current state of radiation and chemical threat research and the role that government agencies such as NIH’s CounterAct program, BARDA, ASPR, and the FDA play in the development of medical countermeasures to mitigate their harmful effects.…”
mentioning
confidence: 99%
“…Marzella’s article addresses the importance of aligning mechanisms of action and clinical conditions in animal models of radiation and chemical threat agents and their use in selecting a maximally effective dose in humans. Rios 10 examines the current state of radiation and chemical threat research and the role that government agencies such as NIH’s CounterAct program, BARDA, ASPR, and the FDA play in the development of medical countermeasures to mitigate their harmful effects.…”
mentioning
confidence: 99%